This article was created and reviewed by experienced healthcare professionals specializing in obesity medicine, wellness, healthy aging, peptide therapy, and bariatric care
Oral formulations deliver peptide to intestinal tissue with less than 10% entering systemic circulation, meaning even dose escalation cannot compensate for the pharmacokinetic barrier
Preclinical (mostly rat) studies show BPC-157 acts like a supercharged project manager that: Builds new blood vessels super fast (angiogenesis) It switches on the VEGF system (the same one your body uses to grow new capillaries) and boosts nitric oxide so fresh blood, oxygen, and nutrients flood the injured area
Further reduction in injury recurrence and chronic pain
Cerovecki, T., Bojanic, I., Brcic, L., Radic, B., Vukoja, I., Seiwerth, S., & Sikiric, P